Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial
暂无分享,去创建一个
H. Genant | J. Kremer | C. Peterfy | P. Emery | R. Westhovens | A. Russell | J. Becker | C. Abud-Mendoza | J. Sibilia
[1] M. Hochberg,et al. Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program , 2013, The Journal of Rheumatology.
[2] C. Bombardier,et al. Serious infections in a population‐based cohort of 86,039 seniors with rheumatoid arthritis , 2013, Arthritis care & research.
[3] M. A. van de Laar,et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry , 2012, Annals of the rheumatic diseases.
[4] H. Genant,et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial , 2011, Annals of the Rheumatic Diseases.
[5] M. Dougados,et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study , 2011, Annals of the Rheumatic Diseases.
[6] S. Ito,et al. Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety , 2011, The Journal of Rheumatology.
[7] P. Emery,et al. Reporting of long-term extension studies: lack of consistency calls for consensus , 2011, Annals of the rheumatic diseases.
[8] P. Durez,et al. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity , 2010, Arthritis research & therapy.
[9] Maurizio Cutolo,et al. Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.
[10] D. Furst. Serum immunoglobulins and risk of infection: how low can you go? , 2009, Seminars in arthritis and rheumatism.
[11] W. Bishai,et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry , 2009, Annals of the rheumatic diseases.
[12] M. Dougados,et al. Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study , 2009, The Journal of Rheumatology.
[13] P Tugwell,et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. , 2008, Arthritis and rheumatism.
[14] M. Hochberg,et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis , 2008, Arthritis research & therapy.
[15] H. Genant,et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. , 2008, Arthritis and rheumatism.
[16] W. Dixon,et al. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis , 2008, Current opinion in rheumatology.
[17] M. Dougados,et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.
[18] H. Genant,et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial , 2007, Annals of the rheumatic diseases.
[19] M. Malaise,et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity , 2006, Arthritis research & therapy.
[20] H. Genant,et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.
[21] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[22] M. Dougados,et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs , 2006, Annals of the rheumatic diseases.
[23] D. Furst,et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study , 2005, Annals of the rheumatic diseases.
[24] Matthias Schneider,et al. Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.
[25] P. V. van Riel,et al. The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.
[26] M. Dougados,et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[27] A. Widmer,et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003, Rheumatology.
[28] L. Kiemeney,et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[29] A Woolf,et al. The links between joint damage and disability in rheumatoid arthritis. , 2000, Rheumatology.
[30] H K Genant,et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. , 1998, Arthritis and rheumatism.
[31] M. Homma. [ACR preliminary definition, of improvement in rheumatoid arthritis]. , 1996, Ryumachi. [Rheumatism].
[32] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[33] G. Alarcón,et al. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. , 1989, Arthritis and rheumatism.
[34] S. Soraci,et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. , 1983, Arthritis and rheumatism.
[35] W. Kröger,et al. Recommendations , 1915, Nature.
[36] M. Suarez‐Almazor,et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. , 2010, Sao Paulo medical journal = Revista paulista de medicina.